AbbVie completes $21 billion buyout of Pharmacyclics

SHARE AbbVie completes $21 billion buyout of Pharmacyclics

AbbVie has completed its $21 billion buyout of Pharmacyclics.

The buyout adds another major revenue producer to Abbvie’s portfolio, which already includes the world’s top-selling drug, Humira. The deal gives the North Chicago-based drugmaker Imbruvica, a blood cancer treatment that Pharmacyclics makes and then markets with Johnson & Johnson’s Janssen Biotech.

Pharmacyclics Inc. will become a subsidiary of AbbVie and operate from its Sunnyvale, California, headquarters.

The buyout comes months after AbbVie Inc. scuttled a $55 billion deal to buy another drugmaker, Shire, after the U.S. government put in place new limitations on the tax benefits of reincorporating overseas. AbbVie would have reincorporated on the British island of Jersey, where Shire is incorporated.

The Latest
Diets that regularly include bioflavonoid-rich foods have been associated with longevity and a reduced risk of cardiovascular disease, diabetes, some types of cancer and neurogenerative diseases.
The shootings include a person seriously wounded by a Chicago police officer in Back of the Yards.
The man, 21, was discovered about 1:15 a.m. in the 3400 block of West 79th Street.
The person was taken to the University of Chicago Medical Center in critical condition.
The former R&B star is set to go to trial in Chicago — again — on Aug. 15. Here’s a rundown of what’s happening and why.